Whistler Center for Carbohydrate Research and Department of Food Science, Purdue University, 745 Agriculture Mall Drive, West Lafayette, IN 47907, USA.
Br J Nutr. 2010 May;103(10):1514-24. doi: 10.1017/S0007114509993515. Epub 2009 Dec 21.
The purpose of this research was to test the hypothesis that starch-entrapped microspheres would produce favourable fermentation profiles and microbial shifts during in vitro fermentation with the faecal microbiota from patients with inflammatory bowel disease (IBD). In vitro fermentation was carried out using a validated, dynamic, computer-controlled model of the human colon (Toegepast Natuurwetenschappelijk Onderzoek gastro-intestinal model-2) after inoculation with pooled faeces from healthy individuals, patients with inactive IBD (Crohn's disease (CD)) or patients with active IBD (ulcerative colitis (UC)). Starch-entrapped microspheres fermented more slowly and produced more butyrate than fructo-oligosaccharides (FOS) when fermented with the faecal microbiota from patients with active UC. When fermented with the microbiota from patients with inactive CD, starch-entrapped microspheres also fermented more slowly but produced similar amounts of butyrate compared with FOS. Starch-entrapped microspheres showed a greater ability to maintain a low pH during simulated-distal colon conditions compared with FOS. After fermentation with the microbiota from inactive CD patients, starch-entrapped microspheres resulted in lower concentrations of some potentially harmful gut bacteria, included in Bacteroides, Enterococcus, Fusobacterium and Veillonella, compared with FOS. These findings suggest that slow fermenting starch-entrapped microspheres may induce a favourable colonic environment in patients with IBD through high butyrate production, maintenance of low pH in the distal colon and inhibition of the growth of potentially harmful bacteria.
淀粉包埋微球在体外发酵时,会与炎症性肠病(IBD)患者的粪便微生物群产生有利的发酵模式和微生物变化。在向健康个体、处于缓解期的 IBD 患者(克罗恩病(CD))或活动期 IBD 患者(溃疡性结肠炎(UC))的粪便样本混合接种后,使用经验证的、动态的、计算机控制的人类结肠模型(应用自然科学研究-2 型肠道模型)进行体外发酵。与果糖低聚糖(FOS)相比,淀粉包埋微球在与活动期 UC 患者的粪便微生物群发酵时,发酵速度更慢,但产生的丁酸更多。当与处于缓解期 CD 患者的粪便微生物群发酵时,淀粉包埋微球的发酵速度也较慢,但产生的丁酸量与 FOS 相似。与 FOS 相比,淀粉包埋微球在模拟远端结肠条件下具有更好的保持低 pH 值的能力。与 FOS 相比,在与处于缓解期 CD 患者的粪便微生物群发酵后,淀粉包埋微球导致一些潜在有害肠道细菌(包括拟杆菌属、肠球菌属、梭菌属和韦荣球菌属)的浓度降低。这些发现表明,缓慢发酵的淀粉包埋微球可能通过高丁酸产生、维持远端结肠的低 pH 值和抑制潜在有害细菌的生长,在 IBD 患者中诱导有利的结肠环境。